Advances in Continuous Flow Left Ventricular Assist Device Support for End Stage Heart Failure - A Therapy in Evolution

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The purpose of this review is to highlight recent advances and challenges in the clinical implementation of continuous flow left ventricular assist devices (CF LVADs) in patients with advanced heart failure. Post approval studies of CF LVAD therapy continue to show a progressive improvement in survival and reduction of adverse events. Major trials are ongoing to compare outcomes of an axial flow device (Heart Mate II) and smaller centrifugal flow pumps (HeartWare VADs and Heart Mate III). Numerous studies have investigated strategies to reduce major hematologic and neurologic adverse events by evaluating hemolysis, antithrombotic therapy, and blood pressure control. This review will present current findings that are centered around the impact of CF LVADs on improving survival and reducing adverse events through an evolution in management and design.

Original languageEnglish (US)
JournalCardiology in Review
DOIs
StateAccepted/In press - Jul 25 2016

Fingerprint

Heart-Assist Devices
Heart Failure
Survival
Hemolysis
Nervous System
Therapeutics
Blood Pressure
Equipment and Supplies

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

@article{feec9dbb323a4894acdf47e2e69872d2,
title = "Advances in Continuous Flow Left Ventricular Assist Device Support for End Stage Heart Failure - A Therapy in Evolution",
abstract = "The purpose of this review is to highlight recent advances and challenges in the clinical implementation of continuous flow left ventricular assist devices (CF LVADs) in patients with advanced heart failure. Post approval studies of CF LVAD therapy continue to show a progressive improvement in survival and reduction of adverse events. Major trials are ongoing to compare outcomes of an axial flow device (Heart Mate II) and smaller centrifugal flow pumps (HeartWare VADs and Heart Mate III). Numerous studies have investigated strategies to reduce major hematologic and neurologic adverse events by evaluating hemolysis, antithrombotic therapy, and blood pressure control. This review will present current findings that are centered around the impact of CF LVADs on improving survival and reducing adverse events through an evolution in management and design.",
author = "Omar Saeed and Jorde, {Ulrich P.}",
year = "2016",
month = "7",
day = "25",
doi = "10.1097/CRD.0000000000000117",
language = "English (US)",
journal = "Cardiology in Review",
issn = "1061-5377",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Advances in Continuous Flow Left Ventricular Assist Device Support for End Stage Heart Failure - A Therapy in Evolution

AU - Saeed, Omar

AU - Jorde, Ulrich P.

PY - 2016/7/25

Y1 - 2016/7/25

N2 - The purpose of this review is to highlight recent advances and challenges in the clinical implementation of continuous flow left ventricular assist devices (CF LVADs) in patients with advanced heart failure. Post approval studies of CF LVAD therapy continue to show a progressive improvement in survival and reduction of adverse events. Major trials are ongoing to compare outcomes of an axial flow device (Heart Mate II) and smaller centrifugal flow pumps (HeartWare VADs and Heart Mate III). Numerous studies have investigated strategies to reduce major hematologic and neurologic adverse events by evaluating hemolysis, antithrombotic therapy, and blood pressure control. This review will present current findings that are centered around the impact of CF LVADs on improving survival and reducing adverse events through an evolution in management and design.

AB - The purpose of this review is to highlight recent advances and challenges in the clinical implementation of continuous flow left ventricular assist devices (CF LVADs) in patients with advanced heart failure. Post approval studies of CF LVAD therapy continue to show a progressive improvement in survival and reduction of adverse events. Major trials are ongoing to compare outcomes of an axial flow device (Heart Mate II) and smaller centrifugal flow pumps (HeartWare VADs and Heart Mate III). Numerous studies have investigated strategies to reduce major hematologic and neurologic adverse events by evaluating hemolysis, antithrombotic therapy, and blood pressure control. This review will present current findings that are centered around the impact of CF LVADs on improving survival and reducing adverse events through an evolution in management and design.

UR - http://www.scopus.com/inward/record.url?scp=84979999702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979999702&partnerID=8YFLogxK

U2 - 10.1097/CRD.0000000000000117

DO - 10.1097/CRD.0000000000000117

M3 - Article

JO - Cardiology in Review

JF - Cardiology in Review

SN - 1061-5377

ER -